Abbott Laboratories announced on November 24, 2025, that it initiated a medical device correction for approximately three million FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitoring sensors across the United States. The Abbott glucose correction follows internal testing that revealed certain sensors from a specific production line may deliver inaccurate low glucose readings, potentially endangering patients who rely on these devices for diabetes management.
The company has received reports of 736 severe adverse events globally and seven deaths associated with this manufacturing defect, though none of the fatalities occurred in the United States. Within the U.S. market alone, 57 severe adverse events have been documented, prompting immediate corrective action from the medical device leader.
Abbott Glucose Correction: Understanding the Manufacturing Defect
The issue stems from a single production line among several facilities manufacturing Libre 3 and Libre 3 Plus sensors. Abbott has identified and resolved the root cause of the defect, enabling continued production without anticipated supply chain disruptions. Approximately half of the affected three million sensors have already expired or been used by patients, narrowing the scope of active devices requiring replacement.
Incorrect low glucose readings pose significant health risks for diabetes patients. When sensors display falsely low glucose levels, patients may consume excessive carbohydrates or delay critical insulin doses, decisions that can result in serious complications including injury or death. The precision of continuous glucose monitors is essential for effective diabetes management, making this Abbott glucose correction a critical patient safety initiative.
Replacement Program and Patient Response Protocol
Abbott has established a comprehensive replacement program through a dedicated website at FreeStyleCheck.com, where patients can verify whether their sensors are affected by entering serial numbers. The company will replace all potentially affected sensors at no charge, with customer service representatives available seven days per week from 8 a.m. to 8 p.m. Eastern Time, plus 24/7 live chat support.
Patients currently wearing or possessing affected sensors should immediately discontinue use and dispose of the devices. Abbott recommends using a blood glucose meter or the built-in meter in the FreeStyle Libre 3 reader to make treatment decisions when sensor readings don’t match symptoms or expectations.
Market Impact and Product Scope
FreeStyle Libre 3 readers and mobile apps remain unaffected by this correction. Additionally, other products in the Libre family—including FreeStyle Libre 14 day, FreeStyle Libre 2, FreeStyle Libre 2 Plus, and FreeStyle Libre Pro sensors—as well as Abbott biowearables continue operating normally without safety concerns.
The FreeStyle Libre 3 system received FDA clearance in May 2022 and represents Abbott’s latest-generation continuous glucose monitoring technology. The device features a compact sensor approximately the size of two stacked U.S. pennies that attaches to the back of the upper arm, automatically streaming glucose readings to smartphones for real-time monitoring.
Global Coordination and Regulatory Response
Abbott is implementing this medical device correction internationally across all markets where Libre 3 and Libre 3 Plus sensors are distributed. Patients in other countries can access information through the same FreeStyleCheck.com portal to determine if their sensors require replacement.
The Abbott glucose correction comes at a significant moment for the company, which recently announced a $21 billion acquisition of Exact Sciences on November 20, 2025. This juxtaposition of growth ambitions and product safety challenges highlights the complex operational landscape medical device manufacturers navigate while maintaining patient safety standards.
Abbott Glucose Correction: Industry Implications
This incident will likely prompt increased scrutiny of quality control processes throughout the diabetes technology sector. Competitor Dexcom has also faced recent challenges with its G7 sensor deployment and issued a recall for its G6 device due to software problems. The pattern of continuous glucose monitor issues across multiple manufacturers suggests potential systemic challenges in sensor manufacturing quality assurance.
For Abbott, which employs approximately 114,000 people globally and serves patients in more than 160 countries, maintaining trust in its diabetes care portfolio remains paramount. The company’s swift identification of the manufacturing defect and comprehensive replacement program demonstrates operational maturity in handling product safety issues, though questions persist about how defective sensors reached consumers initially.
Patients requiring assistance can contact Abbott customer service at 1-833-815-4273 or access live chat support through the company’s website. The Abbott glucose correction underscores the critical importance of rigorous manufacturing quality control in medical devices where patient safety depends on measurement accuracy.
